Mehabe score: 4 G Factor: 7 Piotski Score: 7 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 7 and Piotski score of 7.
Description
Colgate-Palmolive (India) in the business of Personal Care (including Oral Care).Site:COLPALMain Symbol:COLPAL
Stock trades at 1792.0, above its 50dma 1702.76. It also trades above its 200dma 1593.13. The stock remains bullish on techicals
The 52 week high is at 1823.40 and the 52week low is at 1322.15
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– has a good return on equity (ROE) track record: 3 Years ROE 59.46%
– has been maintaining a healthy dividend payout of 91.26%
Weakness
– Stock is trading at 41.81 times its book value
-The company has delivered a poor sales growth of 4.59% over past five years.
Competition
– The industry trades at a mean P/E of 58.6x. Hind. Unilever trades at the industry’s max P/E of 66.81x. COLPAL trades at a P/E of 47.1x
– Industry’s mean G-Factor is 4.5 while the mean Piotski score is 7.0. COLPAL has a G-Factor of 7 and Piotski scoreof 7.
– Average 1 month return for industry is 0.8%. The max 1- month return was given by Colgate-Palmoliv: a return of 7.36 %
Quarterly Results
Sales for period ended Jun 2021 is Rs 1166.0 cr compared to Rs 1041.0 cr for period ended Jun 2020, a rise of 12.0%
Operating Profits reported at Rs 355.0 cr for period ended Jun 2021 vis-vis 308.0 for period ended Jun 2020 .
Operating Margins expanded 85.9 bps for period ended Jun 2021 vis-vis Jun 2020 .
The EPS for Jun 2021 was Rs 8.58 compared to Rs 11.57 for previous quarter ended Mar 2021 and Rs 7.29 for Jun 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 4967.0 cr for period ended TTM vis-vis sales of Rs 4841.0 cr for the period ended Mar 2021, a growth of 2.5%. The 3 year sales cagr stood at 3.6%.
Net Profit reported at Rs 1070.0 cr for period ended TTM vis-vis sales of Rs 1035.0 cr for the period ended Mar 2021, rising 3.3%.
Company recorded a healthy Net Profit CAGR of 11.3% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 75.0% compared to 59.0% over the last 3 Years. – The stock has given a return of 24% on a 1 Year basis vis-vis a return of 17% over the last 3 Years. – The compounded sales growth on a TTM bassis is 7% vis-vis a compounded sales growth of 5% over the last 3 Years. – The compounded profit growth on a TTM basis is 27% vis-vis a compounded profit growth of 15% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Jun 2021 fii holding stood at 18.61% vis-vis 16.9% for Mar 2021 – Public shareholding has remained largely constant. The Jun 2021 public holding stood at 21.89% vis-vis 21.8% for Mar 2021
Conclusion
– is almost debt free.
– has a good return on equity (ROE) track record: 3 Years ROE 59.46%
– has been maintaining a healthy dividend payout of 91.26% – Stock is trading at 41.81 times its book value
-The company has delivered a poor sales growth of 4.59% over past five years.
